Welcome to our dedicated page for Intellia Therape news (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therape stock.
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage gene editing company whose news flow centers on the development of CRISPR-based therapies. Company announcements frequently highlight progress in its in vivo programs, including nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis and lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE). Investors following NTLA news can see updates on clinical trial data, regulatory interactions and platform developments that shape the company’s pipeline.
Recent Intellia press releases and SEC-furnished materials describe longer-term Phase 1 and Phase 1/2 data for nex-z and lonvo-z, pooled analyses of patient outcomes, and details from global Phase 3 trials such as MAGNITUDE, MAGNITUDE-2 and HAELO. News items also cover events such as temporary pauses in patient dosing, FDA clinical holds on Phase 3 nex-z trials, and subsequent company plans to work with regulators. These disclosures provide insight into both the potential and the risks associated with Intellia’s CRISPR-based candidates.
Beyond clinical results, NTLA news includes quarterly financial updates, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), and investor presentations at major healthcare conferences. Together, these items give a view into Intellia’s operational progress, capital position and strategic priorities as it advances gene editing therapies for serious diseases like ATTR amyloidosis and HAE.
This news page aggregates Intellia’s latest press releases and related market-moving information in one place, allowing readers to review clinical milestones, regulatory developments and corporate updates linked to the NTLA stock.
Intellia Therapeutics (NASDAQ:NTLA) reported Q3 2024 financial results and pipeline progress. Key highlights include FDA clearance for MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran in ATTR amyloidosis, strong enrollment in MAGNITUDE Phase 3 study, and active patient screening in HAELO Phase 3 study for hereditary angioedema. The company ended Q3 with $944.7 million in cash. Financial results show $9.1 million in collaboration revenue, R&D expenses of $123.4 million, and a net loss of $135.7 million. Cash runway extends into late 2026.
Intellia Therapeutics (NASDAQ:NTLA) has granted inducement awards to ten new employees under its 2024 Inducement Plan. The grants include 73,459 restricted stock units (RSUs) of common stock, which will vest in three equal installments on November 1, 2025, 2026, and 2027. These awards were granted outside the company's stockholder-approved equity incentive plans and were approved by Intellia's compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA) has announced two upcoming virtual investor events in November 2024. The first event, scheduled for November 7 at 8 a.m. ET, will present third quarter 2024 financial results and operational highlights. The second event, on November 16 at 11 a.m. CT/12 p.m. ET, will showcase new clinical data from the Phase 1 study of nexiguran ziclumeran (nex-z), their investigational CRISPR-based gene editing therapy for transthyretin (ATTR) amyloidosis. The nex-z data presentation follows a late-breaking oral presentation at the 2024 American Heart Association Scientific Sessions in Chicago. This therapy is being developed in collaboration with Regeneron as a single-dose treatment.
Intellia Therapeutics announced positive Phase 2 results for NTLA-2002, their investigational CRISPR gene editing treatment for hereditary angioedema (HAE). The study showed that a single 50 mg dose resulted in a 77% and 81% mean monthly attack rate reduction compared to placebo during weeks 1-16 and 5-16, respectively. Eight of 11 patients in the 50 mg arm remained completely attack-free following a one-time infusion. The treatment demonstrated an encouraging safety profile, with most adverse events being Grade 1 or 2. Based on these results, Intellia has selected the 50 mg dose for their global pivotal Phase 3 HAELO study.
Intellia Therapeutics (NASDAQ:NTLA) has announced a new date for its investor webcast to review NTLA-2002 Phase 2 data. The webcast will now be held on Thursday, October 24 at 8:30 a.m. ET, instead of the previously announced date of October 28, 2024.
This change does not affect the planned oral presentation at the 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Boston, Massachusetts, scheduled for October 24 – 28.
Investors can join the webcast via a provided link or through the Events and Presentations page on Intellia's website. A replay of the webcast will be available on the company's website for at least 30 days following the call.
Intellia Therapeutics (NASDAQ:NTLA) has initiated HAELO, a global Phase 3 study of NTLA-2002, an investigational in vivo CRISPR gene editing treatment for hereditary angioedema (HAE). NTLA-2002 is designed as a single-dose treatment to prevent potentially life-threatening swelling attacks in HAE patients. The study will evaluate the efficacy and safety of NTLA-2002 in 60 adults with Type I or Type II HAE, with patients randomized 2:1 to receive a single 50 mg infusion of NTLA-2002 or placebo.
The primary endpoint is the change in number of HAE attacks from week 5 through week 28. This initiation follows positive safety and efficacy data from the ongoing Phase 1/2 study, which showed dramatic reductions in attack rate and consistent, deep, and durable reductions in kallikrein levels. Detailed results from the Phase 2 portion will be presented at the 2024 ACAAI Annual Scientific Meeting in October.
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on CRISPR-based therapies, has announced the granting of inducement awards to nine new employees under its 2024 Inducement Plan. The awards, granted on October 1, 2024, consist of time-based restricted stock units (RSUs) for 54,944 shares of Intellia's common stock.
The RSUs will vest in three equal installments on October 1 of 2025, 2026, and 2027, subject to the employees' continued service. These awards were granted outside of Intellia's stockholder-approved equity incentive plans, as part of the 2024 Inducement Plan adopted by the board of directors in June 2024. The compensation committee approved the awards as a material inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA) announced that new interim data from the ongoing Phase 1 study of nexiguran ziclumeran (nex-z) will be presented at the 2024 American Heart Association (AHA) Scientific Sessions in Chicago. Nex-z is an investigational in vivo CRISPR-based gene editing therapy designed as a single-dose treatment for transthyretin (ATTR) amyloidosis.
The presentation will include safety data, reduction in serum TTR, biomarkers of disease progression, and functional capacity data in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM). Dr. Marianna Fontana from University College London will present the findings on November 16, 2024, as part of the Late-Breaking Science session.
Intellia is developing nex-z in collaboration with Regeneron as part of a multi-target discovery, development, and commercialization partnership.
Intellia Therapeutics (NASDAQ:NTLA) has announced that detailed results from the Phase 2 study of NTLA-2002, their investigational in vivo CRISPR-based gene editing therapy for hereditary angioedema (HAE), will be presented at the 2024 ACAAI Annual Scientific Meeting. The presentation, titled "Results From a Phase 2, Randomized, Placebo-Controlled Trial of CRISPR-Based Therapy NTLA-2002 for Hereditary Angioedema," will take place on October 26, 2024. This follows a previous positive topline announcement that the study met its primary and all secondary endpoints. Intellia will also host an investor webcast on October 28, 2024, to review the new data.
Intellia Therapeutics (NASDAQ:NTLA), a leading clinical-stage gene editing company, has announced inducement grants for five new employees under its 2024 Inducement Plan. The grants include:
- Non-qualified stock options for 49,751 shares
- Time-based RSUs for 44,154 shares
- Performance-based RSUs for 17,064 shares linked to total stockholder return
- Performance-based RSUs for 12,500 shares tied to development milestones
These equity awards, granted outside of Intellia's stockholder-approved plans, were approved by the compensation committee as a material inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4).